Human evidence of a supra-spinal modulating role of dopamine on pain perception

Synapse

Volumn 63, Issue 5, 2009, Pages 390-402

  Potvin, Stéphane ^a   Grignon, Sylvain ^a   Marchand, Serge ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Dopamine; Genetics; Neuropsychiatric disorders; Pain; PET

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMPHETAMINE; ANTIPARKINSON AGENT; APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DROPERIDOL; FLUPENTIXOL; HALOPERIDOL; KETAMINE; LEVODOPA; METOCLOPRAMIDE; MORPHINE; NALOXONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PRAMIPEXOLE; PROCHLORPERAZINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; UNINDEXED DRUG;

ABNORMAL SENSATION; ANALGESIC ACTIVITY; ARTICLE; BRAIN REGION; CANCER PAIN; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FIBROMYALGIA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; MAJOR DEPRESSION; MIGRAINE; MOLECULAR GENETICS; NEUROIMAGING; NEUROPATHIC PAIN; NEUROPATHOLOGY; NOCICEPTION; NOCICEPTIVE STIMULATION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SHOULDER PAIN; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE; TEMPOROMANDIBULAR JOINT DISORDER; TOBACCO DEPENDENCE;

EID: 66049096950     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20616     Document Type: Article

References (110)

1. Akerman S, Goadsby PJ. 2007. Dopamine and migraine: Biology and clinical implications. Cephalalgia 27:1308-1314.
2. Altier N, Stewart J. 1993. Intra-VTA infusions of the substance P analogue, DimE-C7 and intra-accumbens infusions of amphetamine induce analgesia in the formalin test. Brain Res 628:279-285.
3. Altier N, Stewart J. 1998. Dopamine receptor antagonists in the nucleus accumbens attenuate analgesia induced by ventral tegmental area substance P or morphine and by nucleus accumbens amphetamine. J Pharmacol Exp Ther 285:208-215.
4. Altier N, Stewart J. 1999. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 65:2269-2287.
5. Andersen OK, Felby S, Nikolajsen L, Bjerring P, Jensen TS, Arendt-Nielsen L. 1996. The effect of ketamine on stimulation of primary and secondary hyperalgesic areas induced by capsaicin - A double-blind, placebo-controlled, human experimental study. Pain 66:51-62.
6. Arendt-Nielsen L, Brennum J, Sindrup S, Bark P. 1994. Electrophysiological and psychophysical quantification of temporal summation in the human nociceptive system. Eur Appl Physiol Occup Physiol 68:266-273.
7. Armero P, Muriel C, Santos J, Sanchez-Montero FJ, Rodriguez RE, Gonzalez-Sarmiento R. 2005. COMT (Val158Met) polymorphism is not associated to neuropathic pain in a Spanish population. Eur J Pain 9:229-232.
8. Bell RF, Eccleston C, Kalso E. 2003. Ketamine as adjuvant to opioids for cancer pain: A qualitative systematic review. J Pain Symptom Manage 26:867-875.
9. Bleuler E. 1911. Textbook of psychiatry. New York: Dover Publications.
10. Blumensohn R, Ringler D, Eli I. 2002. Pain perception in patients with schizophrenia. J Nerv Ment Dis 190:481-483.
11. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O. 2005. Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study. Mov Disord 20:1557-1563.
12. Cendan CM, Pujalte JM, Portillo-Salido A, Baeyens JM. 2005. Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology 182:485-493.
13. Chevlen E, Davis PS, Rhiner M. 2005. From mechanisms to management: translating the neuropathic pain consensus recommendations into clinical practice. J Am Acad Nurse Pract 17:3-17.
14. Clarke PBS, Franklin KBJ. 1992. Infusions of 6-hydroxydopamine into the nucleus accumbens abolish the analgesic effect of amphetamine but not of morphine in the formalin test. Brain Res 580:106-110.
15. Coffeen U, Lopez-Avila A, Ortega-Legaspi JM, Del Angel R, Lopez-Munoz FJ, Pellicer F. 2008. Dopamine receptors in the anterior insular cortex modulate long-term nociception in the rat. Eur J Pain 12:535-543.
16. Cutler AJ. 2003. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28:69-82.
17. Dalal S, Melzak R. 1998. Potentiation of opioid analgesia by psychostimulant drugs: A review. J Pain Symptom Manage 16:245-253. (Pubitemid 28478238)
18. Damaj MI, Zheng J, Martin BR, Kuhar MJ. 2006. Intrathecal CART (55-102) attenuates hyperalgesia and allodynia in a mouse model of neuropathic but not inflammatory pain. Peptides 27:2019-2023.
19. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. 2005. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14:135-143.
20. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB, Goldman D, Maixner W. 2006. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125:216-224.
21. Dickenson AH, Sullivan AF. 1987. Evidence for a role of the NMDA receptor in the frequency dependent potential of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropsychopharmacology 26:1235-1238.
22. Dworkin RH, Clark CW, Lipsitz JD, Amador XF, Kaufman CA, Opler LA, White SR, Gorman JM. 1993. Affective deficits and pain insensitivity in schizophrenia. Motiv Emotion 17:245-276.
23. Dwoskin LP, Rauhut AS, King-Prospisil KA, Bardo MT. 2006. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178-207.
24. Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. 2004. Do the second-generation "atypical neuroleptics" have analgesic properties? A structured evidence-based review. Pain Med 5:359-365.
25. Franklin KBJ. 1998. Analgesia and abuse potential: An accidental association or a common substrate? Pharmacol Biochem Behav 59:993-1002.
26. Frichionne G, Stefano GB. 2005. Placebo neural systems: nitric oxide and the dopamine brain reward and motivation circuitries. Med Sci Monit 11:54-65.
27. Garcia-Fructuoso FJ, Lao-Villadoniga JI, Beyer K, Santos C. 2006. Relationship between catechol-O-methyltransferase genotypes and fibromyalgia's severity. Rheumatol Clin 2:168-172.
28. Gear RW, Aley KO, Levine JD. 1999. Pain-induced analgesia mediated by mesolimbic reward circuits. J Neurosci 19:7175-7181.
29. Gerdelet-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, Brefel-Courbon C. 2007. Levodopa raises objective pain threshold in Parkinson's disease: A RIII reflex study. J Neurol Neurosurg Psychiatry 78:1140-1142.
30. George SZ, Wallace MR, Wright TW, Moser MW, Greenfield III WH, Sack BK, Herbstman DM, Fillingim RB. 2008. Evidence for a biopsychosocial influence on shoulder pain: Pain catastrophizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings. Pain 136:53-61.
31. Giuffrida R, Vingerhoets FJ, Bogousslavsky J, Ghika J. 2005. Pain in Parkinson's disease (French). Rev Neurol 161:407-418.
32. Gorelick DA, Cornish JL. 2003. The pharmacology of cocaine, amphetamines and other stimulants. In: Graham AW, Schulz TK, Mayo-Smith MF, Ries RK, Wilford BB, editors. Principles of addiction medicine, 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine. p 157-192.
33. Guieu R, Pouget J, Serratrice G. 1992. Nociceptive threshold and Parkinson disease (French). Rev Neurol 148:641-644.
34. Gürsoy S, Erdal E, Herken H, Madenci E, Alasehirli B. 2001. Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int 21:58-61.
35. Gürsoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. 2003. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 23:104-107.
36. Gürsoy S, Erdal E, Sezgin M, Barlas IO, Aydeniz A, Alasehirli B, Sahin G. 2008. Which genotype of MAO gene that the patients have are likely to be most susceptible to the symptoms of fibromyalgia? Rheumatol Int 28:307-311.
37. Hagelberg N, Martikainen IK, Mansikka H, Hinkka S, Nagren K, Hietala J, Scheinin H, Pertovaara A. 2002. Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain 99:273-279.
38. Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luutonen S, Nagren K, Jaaskelainen S. 2003a. Striatal D1 and D2 receptors in burning mouth syndrome. Pain 101:149-154.
39. Hagelberg N, Forssell H, Aalto S, Rinne JO, Scheinnin H, Taimien T, Nagren K, Eskola O, Jaaskelainen SK. 2003b. Altered dopamine D2 receptor binding in atypical facial pain. Pain 106:43-48.
40. Holman AJ, Myers RR. 2005. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52:2495-2505.
41. Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. 2006. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache 46:781-787.
42. Izenwasser S, Kornetsky C. 1988. Potentiation of morphine analgesia by D-amphetamine is mediated by norepinephrine and not dopamine. Pain 33:363-368.
43. Jaaskelainen SK, Forssell H, Tenovuo O. 1997. Abnormalities of the blink reflex in burning mouth syndrome. Pain 73:455-460.
44. Jaaskelainen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, Sonninen P, Bergman J. 2001. Role of the dopaminergic system in chronic pain - A fluorodopa-PET study. Pain 90:257-260.
45. Jochum T, Letzsch A, Greiner W, Wagner G, Sauer H, Bär KJ. 2006. Influence of antipsychotic medication on pain perception in schizophrenia. Psychiatry Res 142:151-156.
46. Julien N, Goffaux P, Arsenault P, Marchand S. 2005. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 114:295-302.
47. Kapur S, Seeman P. 2002. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors - Implications for models of schizophrenia. Mol Psychiatry 7:837-844.
48. Katz J, Pennella-Vaughan J, Hetzel RD, Kanazi GE, Dworkin RH. 2005. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain 6:656-661.
49. Kim H, Neubert JK, Miguel AS, Krishnaraju RK, Idarola MJ, Goldman MJ, Dionne RA. 2004. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 109:488-496.
50. Kim H, Lee H, Rowan J, Brahim J, Dionne RA. 2006a. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain 2:24.
51. Kim H, Mittal DP, Iadarola MJ, Dionne RA. 2006b. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J Med Genet 43:e40.
52. Koob GF, Le Moal M. 2001. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24:97-129.
53. Kraepelin E. 1919. Dementia praecox and paraphrenia. Edinburgh, Scotland: Livingston.
54. Laruelle M, Abi-Dargham A. 1999. Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 13:358-371.
55. Le Bars D, Dickenson AH, Besson JM. 1979a. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 6:283-304.
56. Le Bars D, Dickenson AH, Besson JM. 1979b. Diffuse noxious inhibitory controls (DNIC). II, Lack of effect on non-convergent neurones, supraspinal involvement and theoretical implications. Pain 6:305-327.
57. Liddle PF. 2000. Schizophrenic syndromes. In: Lidow MS, editor. Neurotransmitter receptors in actions of antipsychotic medications. Boca Raton: CRC Press. p 1-15.
58. Lin Y, Morrow TJ, Kiritsy-Roy JA, Casey KL. 1989. Cocaine: Evidence for supraspinal, dopamine-mediated, non-opiate analgesia. Brain Res 479:306-312.
59. Lopez-Avila A, Coffeen U, Ortega-Legaspi JM, del Angel, Pellicer F. 2004. Dopamine and NMDA systems modulate long-term nociception in the rat anterior cingulated cortex. Pain 111:136-143.
60. Lorenz J, Minoshima S, Casey KL. 2003. Keeping pain out of the mind: The role of the dorsolateral prefrontal cortex in pain modulation. Brain 126:1079-1091.
61. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. 2003. Altered dopamine D2 receptor function in fibromyalgia patients: A neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 75:77-82.
62. Marchand S. 2005. Chapitre 1: Neurophysiologie de la douleur. In: Beaulieu P, editor. Pharmacologie de la douleur. Montréal: Les Presses de l'Université de Montréal. p 3-37.
63. Martikainen IK, Hagelberg N, Mansikka H, Hietala J, Nagren K, Scheinin H, Pertovaara A. 2005. Association of striatal D2/D3 receptor binding potential with pain but not tactile sensitivity or placebo analgesia. Neurosci Lett 376:149-153.
64. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. 2003. Serotonin receptors: Their key role in drugs to treat schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 27:1159-1172
65. Millan MJ. 2002. Descending control of pain. Prog Neurobiol 66:355-474.
66. Morgan MJ, Franklin KB. 1990. 6-Hydroxydopamine lesions of the ventral tegmentum abolish D-amphetamine and morphine analgesia in the formalin test but not the tail flick test. Brain Res 519:144-149.
67. Munro G. 2007. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test. Eur J Pharmacology 575:66-74.
68. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. 2006. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314:1930-1933.
69. Nestler EJ, Hyman SE, Malenka RC, editors. 2001. Catecholamines. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Chapter 8. New York: The McGraw-Hill Companies Inc. p 167-190.
70. Perrotta A, Serrao M, Bartolo M, Valletta L, Locuratolo N, Pujia F, Fattapposta F, Bramanti P, Amabile GA, Pierelli F, Parisi L. 2005. Abnormal head nociceptive withdrawal reaction to facial nociceptive stimuli in Parkinson's disease. Clin Neurophysiol 116:2091-2098.
71. Pertovaara A, Mecke E, Calson S. 1991. Attempted reversal of cocaine-induced antinociceptive effects with naloxone, an opioid antagonist. Eur J Pharmacol 192:349-353.
72. Pertovaara A, Martikainen IK, Hagelberg N, Mansikka H, Nagren K, Hietala J, Scheinin H. 2004. Striatal dopamine D2/D3 receptor availability correlates with individual response characteristics to pain. Eur J Neurosci 20:1587-1592.
73. Peyron R, Laurent B, Garcia-Larrea L. 2000. Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol Clin 30:263-288.
74. Potvin S, Stip E, Lipp O, Tempier R, Bentaleb AL, Lalonde P, Goffaux P, Marchand S. 2008. Pain perception in schizophrenia: mo changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization to thermal pain in schizophrenia. J Psychiatr Res 2008;42(12):1010-1016.
75. Potvin S, Marchand S. 2008. Hypoalgesia in schizophrenia is independent of antipsychotic drugs: A systematic quantitative review. Pain 2008;138(1):70-78.
76. Rainville P. 2002. Brain mechanisms of pain affect and pain modulation. Curr Opin Neurobiol 12:195-204.
77. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. 1997. Pain affect encoded in the human anterior cingulate but not somatosensory cortex. Science 277:968-971.
78. Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. 2005. The Val158Met polymorphism of the human catechol-O- methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116:73-78.
79. Reyes-Gibby CC, Shete S, Ravkag T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad. 2006. Exploring the join effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130:25-30.
80. Richebé P, Rivat C, Rivalan B, Maurette P, Simonnet G. 2005. Low doses ketamine: antihyperalgesic drug, non-analgesic (french). Ann Fr Anesth Reanim 24:1349-1359.
81. Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. 2002. Palliative uses of methylphenidate in patients with cancer: A review. J Clin Oncol 20:335-339. (Pubitemid 34032629)
82. Sage JI. 2004. Pain in Parkinson's disease. Curr Trend Options Neurol 6:191-200.
83. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. 2003. Update on burning mouth syndrome: overview and patient management. Crit Rev Biol Med 4:275-291.
84. Schestatsky P, Kumru H, Valls-Solé J, Valldeoriola F, Marti MJ, Tolosa E, Chaves ML. 2007. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69:2162-2169.
85. Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG. 1999. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 64:75-80.
86. Scott DJ, Heitzeg MM, Koeppe RA, Stohler CS, Zubieta JK. 2006. Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine. J Neurosci 26:10789-10795.
87. Scott DJ, Stohler CS, Koeppe RA, Zubieta JK. 2007a. Time-course in (11C)carfentanil and (11C)raclopride binding potential after a nonpharmacological challenge. Synapse 61:707-714.
88. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. 2007b. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55:325-336.
89. Seeman P. 2002. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 47:27-38.
90. Semenchuk MR, Sherman S, Davis B. 2001. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57:1583-1588.
91. Shimizu T, Iwata S, Morioka H, Masuyama T, Fukuda T, Nomoto M. 2004. Antinociceptive mechanism of L-DOPA. Pain 110:246-249.
92. Singh MK, Giles LL, Nasrallah HA. 2006. Pain insensitivity in schizophrenia: Trait or state marker? J Psychiatr Pract 12:90-102.
93. Siow HC, Young WB, Silberstein SD. 2005. Neuroleptics in headache. Headache 45:358-371.
94. Slade GD, Diatchenko L, Bhalang K, Sigurdsson A, Fillingim RB, Belfer I, Max MB, Goldman D, Maixner W. 2007. Influence of psychological factors on risk for temporomandibular disorders. J Dent Res 86:1120-1125.
95. Song JY, Yi JH. 2000. Pain insensitivity and pressure pain thresholds in patients with schizophrenia. J Korean Neuropsychiatr Assoc 39:14-21.
96. Su SY, Chen JH, Lai CC, Chen CM, Tsai FJ. 2007. The association between fibromyalgia and polymorphism of monoamine oxidase A and interleukin-4. Clin Rheumatol 26:12-16.
97. Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G. 2006. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 77:822-825.
98. 2 laser evoked potentials. Pain 136:117-124.
99. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, Vargas A, Vargas A, Lao-Villadoniga JI, Garcia-Fructuoso F, Ramos-Kuri M, Hernandez F, Springall R, Bojalil R, Vallejo M, Martinez-Lavin M. 2007. Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 9:R110.
100. Vicentic A, Jones DC. 2007. The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction. J Pharmacol Exp Ther 320:499-506.
101. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S. 2003. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol 478:155-159.
102. Willis WD. 2001. Role of neurotransmitters in sensitization of pain responses. Ann NY Acad Sci 933:142-156.
103. Wood PB, Patterson JC, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. 2007a. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. J Pain 8:51-58. (Pubitemid 46026964)
104. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, Bushnell CM, Chizh BA. 2007b. FIbromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 25:3576-3582.
105. Wood PB. 2006a. Mesolimbic dopaminergic mechanisms and pain control. Pain 120:230-234.
106. Wood PB. 2006b. A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J Pain 7:611-614.
107. Wood PB. 2004. Stress and dopamine: Implications for the pathophysiology of chronic widespread pain. Med Hypotheses 62:420-424.
108. Zigmond MJ, Burke RE. 2002. Pathophysiology of Parkinson's disease. In: Davis et al., editors. Neuropsychopharmacology: The fifth generation of progress. Philadelphia: Lippincott, Williams & Wilkins. p 1781-1793.
109. Zinkstok J, van Amelsvoort T, de Haan L, Baas F, Linszen D. 2005. The catechol-O-methyltransferase gene and schizophrenia. In: Lang MV, editor. Trends in schizophrenia research. New York: Nova Biomedical Books, Chapter IV. p 45-78.
110. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D. 2003. COMT Val158Met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 299:1240-1243.